Activation of P62/SQSTM1-Keap1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Jun 23

PMID 29930914

Citations 55

Authors

Yoshinobu Ichimura

Masaaki Komatsu

Affiliations

Soon will be listed here.

Abstract

Autophagy and the Keap1-Nrf2 system are major cellular defense mechanisms against metabolic and oxidative stress. These two systems are linked phosphorylation of the ubiquitin binding autophagy receptor protein p62/SQSTM1 in the p62-Keap1-Nrf2 pathway. The p62-Keap1-Nrf2 pathway plays a protective role in normal cells; however, recent studies indicate that this pathway induces tumorigenesis of pre-malignant cells, and promotes the growth and drug resistance of tumor cells metabolic reprogramming mediated by Nrf2 activation. These findings suggest that impairment of autophagy is involved in the acquisition of malignancy and maintenance of tumors, and furthermore, that p62/SQSTM1 could be a potential target for chemotherapy in cancers that harbor excess p62.

Citing Articles

KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.

Oskomic M, Tomic A, Barbaric L, Matic A, Kindl D, Matovina M Cancers (Basel). 2025; 17(3).

PMID: 39941813 PMC: 11816071. DOI: 10.3390/cancers17030447.

Nrf2/Keap1/ARE regulation by plant secondary metabolites: a new horizon in brain tumor management.

Dewanjee S, Bhattacharya H, Bhattacharyya C, Chakraborty P, Fleishman J, Alexiou A Cell Commun Signal. 2024; 22(1):497.

PMID: 39407193 PMC: 11476647. DOI: 10.1186/s12964-024-01878-2.

Autophagy and cancer therapy.

Pimentel J, Zhou J, Wu G Cancer Lett. 2024; 605:217285.

PMID: 39395780 PMC: 11665950. DOI: 10.1016/j.canlet.2024.217285.

Toward a CRISPR-based mouse model of -deficient clear cell kidney cancer: Initial experience and lessons learned.

Stransky L, Gao W, Schmidt L, Bi K, Ricketts C, Ramesh V Proc Natl Acad Sci U S A. 2024; 121(41):e2408549121.

PMID: 39365820 PMC: 11474080. DOI: 10.1073/pnas.2408549121.

TRIM44, a Novel Prognostic Marker, Supports the Survival of Proteasome-Resistant Multiple Myeloma Cells.

Vu T, Wang Y, Fowler A, Simieou A, McCarty N Cells. 2024; 13(17.

PMID: 39273003 PMC: 11394402. DOI: 10.3390/cells13171431.

References

Park J, Oh S, Lee D, Lee Y, Sung S, Ji H . p62/SQSTM1 is required for the protection against endoplasmic reticulum stress-induced apoptotic cell death. Free Radic Res. 2016; 50(12):1408-1421. DOI: 10.1080/10715762.2016.1253073. View

Carroll B, Otten E, Manni D, Stefanatos R, Menzies F, Smith G . Oxidation of SQSTM1/p62 mediates the link between redox state and protein homeostasis. Nat Commun. 2018; 9(1):256. PMC: 5772351. DOI: 10.1038/s41467-017-02746-z. View

Lam H, Baglini C, Lope A, Parkhitko A, Liu H, Alesi N . p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. Cancer Res. 2017; 77(12):3255-3267. PMC: 5485875. DOI: 10.1158/0008-5472.CAN-16-2458. View

Todoric J, Antonucci L, Caro G, Li N, Wu X, Lytle N . Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell. 2017; 32(6):824-839.e8. PMC: 5730340. DOI: 10.1016/j.ccell.2017.10.011. View

Rogov V, Dotsch V, Johansen T, Kirkin V . Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol Cell. 2014; 53(2):167-78. DOI: 10.1016/j.molcel.2013.12.014. View

Yan X, Zhang Y, Zhang J, Zhang L, Liu Y, Wu Y . p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells. Cancer Sci. 2017; 108(7):1405-1413. PMC: 5497928. DOI: 10.1111/cas.13276. View

Rolland P, Madjd Z, Durrant L, Ellis I, Layfield R, Spendlove I . The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer. 2007; 14(1):73-80. DOI: 10.1677/erc.1.01312. View

Lee Y, Chou T, Pittman S, Keith A, Razani B, Weihl C . Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA Domain Ubiquitination. Cell Rep. 2017; 19(1):188-202. PMC: 5395095. DOI: 10.1016/j.celrep.2017.03.030. View

Kageyama S, Saito T, Obata M, Koide R, Ichimura Y, Komatsu M . Negative Regulation of the Keap1-Nrf2 Pathway by a p62/Sqstm1 Splicing Variant. Mol Cell Biol. 2018; 38(7). PMC: 5854834. DOI: 10.1128/MCB.00642-17. View

10.

Pilli M, Arko-Mensah J, Ponpuak M, Roberts E, Master S, Mandell M . TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity. 2012; 37(2):223-34. PMC: 3428731. DOI: 10.1016/j.immuni.2012.04.015. View

11.

Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S . Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci. 2012; 103(4):760-6. PMC: 7659245. DOI: 10.1111/j.1349-7006.2012.02216.x. View

12.

Mizushima N, Komatsu M . Autophagy: renovation of cells and tissues. Cell. 2011; 147(4):728-41. DOI: 10.1016/j.cell.2011.10.026. View

13.

Taguchi K, Motohashi H, Yamamoto M . Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011; 16(2):123-40. DOI: 10.1111/j.1365-2443.2010.01473.x. View

14.

Liu J, Chen F, Lung J, Lo C, Lee F, Lu Y . Prognostic significance of p62/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma. Br J Cancer. 2014; 111(5):944-54. PMC: 4150268. DOI: 10.1038/bjc.2014.355. View

15.

Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R . SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell. 2013; 24(6):738-50. PMC: 3910168. DOI: 10.1016/j.ccr.2013.10.025. View

16.

Komatsu M, Waguri S, Koike M, Sou Y, Ueno T, Hara T . Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007; 131(6):1149-63. DOI: 10.1016/j.cell.2007.10.035. View

17.

Matsumoto G, Wada K, Okuno M, Kurosawa M, Nukina N . Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins. Mol Cell. 2011; 44(2):279-89. DOI: 10.1016/j.molcel.2011.07.039. View

18.

Ellis R, Horswell S, Ness T, Lumsdon J, Tooze S, Kirkham N . Prognostic impact of p62 expression in cutaneous malignant melanoma. J Invest Dermatol. 2013; 134(5):1476-1478. PMC: 3954816. DOI: 10.1038/jid.2013.497. View

19.

Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K . p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun. 2016; 7:12030. PMC: 4931237. DOI: 10.1038/ncomms12030. View

20.

Totoki Y, Tatsuno K, Covington K, Ueda H, Creighton C, Kato M . Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014; 46(12):1267-73. DOI: 10.1038/ng.3126. View